Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

The company's Alzheimer's drug is showing promise in clinical trials.

Why Biogen Stock Popped as Much as 37.1% This Week

Constellation Energy Corp

Charter Communications

Intel

MercadoLibre

Match Group

Netflix

Okta

PayPal

Zoom Video

Constellation Energy was the best performer in the Nasdaq 100 for the third quarter. Okta was the worst.

The 5 Best—and 5 Worst—Nasdaq 100 Stocks in Third Quarter

Eisai and Biogen get another chance. Still not a cure, but a big step forward even though it's still just a glimmer of hope for Alzheimer's sufferers. The big news is that lecanemab produced a measurable effect for slowing early Alzheimer's.

Eisai, Biogen And Alzheimer's: Never Say Die, Lecanemab To The Rescue

Alzheimer's drug development companies have been handed a boost in share prices this week following data for the pioneering treatment lecanemab. Positive late-stage clinical data announced by Biogen Inc (NASDAQ:BIIB) and Eisai for the drug, which is an amyloid-targeting antibody, showed it successfully reduced the rate of cognitive decline in Alzheimer's patients (AD).

Biogen and Alzheimer's drug development companies surge on positive clinical data

CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. RoACTEMRA® is indicated in Europe as an intravenous formulation for severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate, moderate to severe rheumatoid arthritis in adults who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists, as well as for the treatment of patients from 2 years of age with juvenile idiopathic polyarthritis who have responded inadequately to previous therapy with methotrexate, patients from 2 years of age with active systemic juvenile idiopathic arthritis who have responded inadequately to prior therapy with NSAIDs and systemic corticosteroids. RoACTEMRA® is also used to treat chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults or paediatric patients 2 years of age or older, and severe coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. The MAA includes positive Phase 32 data for BIIB800 from the clinical program of a multicenter, multinational, randomized, double-blind, parallel-group, active-control study, designed to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of BIIB800 compared to RoACTEMRA® in 621 patients with moderate to severe rheumatoid arthritis with inadequate response to methotrexate. The Phase 3 data from the comparative clinical trial demonstrated that the biosimilar candidate BIIB800 has equivalent efficacy and a comparable PK, safety and immunogenicity profile to reference tocilizumab and these positive results were presented at the European Congress of Rheumatology on June 3, 2022.

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

Biogen and Eisai announce positive clinical results for lecanemab, a novel treatment for Alzheimer's disease. Lecanemab continues the collaboration between the companies, after the controversial approval of Aduhelm last year.

Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug

New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past.

Is Biogen a Smart Biotech Stock to Buy Right Now?

Biogen Inc. (NASDAQ:BIIB) gained more than 48% on Wednesday's stock premarket. The stock was among the top trends on popular social trading platforms.

Biogen stock pumps 48% amid upgrade. What to watch out for

Biogen revealed data from a Phase 3 registrational study of Alzheimer's therapy Lecanemab last night. The drug was able to show a 27% improvement vs. placebo in its primary endpoint measure of Clinical Dementia Rating-Sum of Boxes.

Biogen's Lecanemab Data Blows Alzheimer's Race Open Again

Patients taking the drug showed a 27% decrease in cognitive decline, compared to a control group.

New Alzheimer's drug slows disease in major clinical trial: ‘Blockbuster potential'

Eli Lilly

Amid a notable positive session for the major equity indices, Biogen (NASDAQ: BIIB ) really got the party started with a massive 37% boost in the early afternoon session on Wednesday. Biogen disclosed very encouraging results for its final-phase test for lecanemab, an experimental therapeutic for Alzheimer's disease.

Biotech Stocks LLY, ESALY Gain on Biogen's Positive Trial Results

Biogen's Alzheimer's drug results are breathing new life into a class of anti-amyloid drugs that had been partially written off.

Alzheimer's Blockbuster Might Spur Investor Bonanza, Higher Medicare Costs

Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.

Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study

Shares of Biogen Inc (NASDAQ: BIIB) shot up 40% on Wednesday after the biotech firm said its experimental Alzheimer's drug showed promising results in a Phase III trial.

Biogen stock shot up 40% on Wednesday: find out why

Prothena

Positive results for Biogen's Alzheimer's disease candidate are boosting all three stocks.

Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today

A new drug found to reduce cognitive decline in early-stage Alzheimer's has been hailed as an "historic moment" in the treatment of the disease.

'Historic moment' in Alzheimer's treatment as trial drug slows cognitive decline

Today, we have a win-win for everyone except the short sellers. Biogen (NASDAQ: BIIB ) and Japanese pharmaceutical firm Eisai (OTCMKTS: ESALY ) are co-developing an experimental Alzheimer's disease drug called lecanemab.

Why Is Biogen (BIIB) Stock Up 40% Today?

An experimental Alzheimer's disease treatment developed by Eisai and Biogen that appears to slow cognitive decline sent shares in both companies soaring, but some analysts are tempering their expectations until they get a better idea if Medicare will pay for the drug.

Medicare coverage of Eisai and Biogen's promising new Alzheimer's therapy is ‘another bridge to cross'

A study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over an 18-month period.

Biogen shares soar on Alzheimer's drug developments

JPMorgan estimates the Alzheimer's drug could generate between $6 billion and $10 billion in peak sales.

Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study

The company said Tuesday its new Alzheimer's treatment reduced cognitive decline by 27% compared to a placebo group in a late-stage clinical trial.

Biogen Stock Jumps 35% After Promising Results For New Alzheimer's Drug

Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a final-phase test. The post Biogen Explodes Higher After Alzheimer's Drug Succeeds In Final-Phase Test appeared first on Investor's Business Daily.

Biogen Explodes Higher After Alzheimer's Drug Succeeds In Final-Phase Test

The news could be good for patients suffering from a debilitating disease.

A Biotech Breakthrough Means Big Gains for These 2 Stocks

The shares of Biogen Inc (NASDAQ:BIIB) are seeing an unprecedented surge ahead of the open, last seen up 53.2% at $302.91 after announcing that the experimental Alzheimer's drug it developed in conjunction with Japanese pharmaceutical name Eisai succeeded in late-stage trials.

Biogen Stock Surges More Than 50% in Premarket Trading

Biogen Inc (NASDAQ: BIIB) shares are trading higher by 42.62% to $282.08 during Wednesday's pre-market session after the company and Eisai Co.

News for Biogen Stock (BIIB)